Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.46 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906492 | 0.91 | PDE4A (0.49) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8421549 | 0.89 | PDE4A (0.47) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6690200 | 0.89 | TDP1 (0.49) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3134558 | 0.89 | HDAC1 (0.50) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9435466 | 0.87 | CCNE2 (0.47) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14548958 | 0.86 | HDAC1 (0.55) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13609069 | 0.85 | HTT (0.57) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23453027 | 0.85 | HTT (0.51) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7852208 | 0.85 | HDAC1 (0.43) | HDAC1HDAC2NPC1RAB9APOLB | |
| SCHEMBL13196022 | 0.84 | NPC1 (0.45) | TDP1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074911-B | Peptide nucleic acid monomers and oligomers | 优基艾森斯股份公司 | 2020-11-03 | — | — | CN | disclosed |
| US-20170166900-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | UGISENSE AG (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20170002355-A1 | cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY | THE USA, AS REPRESENTED BY THE SECRETARY, DEPART- MENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170002355-A1 | cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY | THE USA, AS REPRESENTED BY THE SECRETARY, DEPART- MENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-05 | — | — | US | disclosed |
| EP-2569328-B1 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | US HEALTH (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015112438-A1 | cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20140148500-A1 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-05-29 | — | — | US | disclosed |
| US-20140148500-A1 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-05-29 | — | — | US | disclosed |
| EP-2174936-B1 | PNA monomer and precursor | PANAGENE INC (KR) | 2013-09-04 | — | — | EP | disclosed |
| WO-2011143323-A2 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2011-11-17 | — | — | WO | disclosed |
| US-5831014-A | OLIGOMERS WITH PEPTIDE NUCLEIC ACID UNITS AND AMINO ACID UNITS | ISIS PHARMACEUTICALS, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0618923-A4 | PEPTIDE NUCLEIC ACIDS AND THEIR EFFECT ON GENETIC MATERIAL. | GLAXO INC (US) | 1998-05-20 | — | — | EP | disclosed |
| EP-0777678-A4 | — | — | 1997-07-16 | — | — | EP | disclosed |
| EP-0777678-A1 | PNA COMBINATORIAL LIBRARIES AND IMPROVED METHODS OF SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0773950-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996002558-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| WO-1995023163-A1 | PNA COMBINATORIAL LIBRARIES AND IMPROVED METHODS OF SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| EP-0646595-A1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1995-04-05 | — | — | EP | disclosed |
| EP-0618923-A1 | PEPTIDE NUCLEIC ACIDS AND THEIR EFFECT ON GENETIC MATERIAL | GLAXO WELLCOME INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993012129-A1 | PEPTIDE NUCLEIC ACIDS AND THEIR EFFECT ON GENETIC MATERIAL | GLAXO INC. (US) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166900-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | DTYMK, POLM, PNKP | TDP1 615/4885PDE4A 2912/4885PDE4B 3557/4885 |
| US-20170002355-A1 | cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY | CGAS, STING1, IAPP | TDP1 56/4885PDE4A 528/4885PDE4B 808/4885 |
| US-20140148500-A1 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | NCL, PARN, COIL | TDP1 662/4885PDE4A 1813/4885PDE4B 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.